Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals Inc. has dosed the first participant in the open-label extension phase of its Phase 2 ALTITUDE-AD clinical trial for early Alzheimer’s disease. Participants who completed the initial 18-month placebo-controlled portion will receive sabirnetug at 35 mg/kg intravenously every four weeks for an additional 52 weeks. The study will monitor clinical measures and safety, with topline results expected in late 2026.
Acumen Pharmaceuticals Inc. has announced the dosing of the first participant in the open-label extension (OLE) phase of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in individuals with early Alzheimer’s disease. This extension allows participants who completed the initial 18-month placebo-controlled portion to receive sabirnetug at 35 mg/kg intravenously every four weeks for an additional 52 weeks. The study will continue to monitor clinical measures and safety. Sabirnetug is a humanized monoclonal antibody targeting soluble amyloid beta oligomers. Topline results from the ALTITUDE-AD trial are expected to be reported in late 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576363-en) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
